Shopping Cart
Remove All
Your shopping cart is currently empty
TNCA (Synonyms: Lycoperodine-1)
Catalog No. T7716 Copy Product Info
Purity: 97.73%
🥰Excellent
TNCA (Lycoperodine-1) is a high-affinity CaSR ligand (CaSRL) with co-agonist activity.
TNCA
Copy Product Info🥰Excellent
Catalog No. T7716
Synonyms Lycoperodine-1
TNCA (Lycoperodine-1) is a high-affinity CaSR ligand (CaSRL) with co-agonist activity.
Cas No. 42438-90-4
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | $31 | In Stock | In Stock | |
| 25 mg | $52 | In Stock | In Stock | |
| 50 mg | $81 | In Stock | In Stock | |
| 100 mg | $123 | In Stock | In Stock | |
| 500 mg | $297 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.73%
Appearance:Solid
Color:White to Red
Contact us for more batch information
Product Introduction
TNCA AI Summary
TNCA displays notable bioactivity across several domains, primarily showing significant inhibitory effects on platelet aggregation and thrombus formation. In vitro studies using rabbit blood reveal that it notably affects platelet aggregation induced by adenosine diphosphate (ADP) and platelet activating factor (PAF) at varying doses. This compound also impacts the adhesion of high pulmonary metastatic SACC-LM cells and platelets, alongside reducing wet and dry thrombus weights in male Wistar anesthetized rats.
Furthermore, in pig blood assays, TNCA demonstrates inhibitory activity on several platelet aggregation pathways, with IC50 values approximate to 3300 nM for ADP, arachidonic acid, PAF, and thrombin-induced platelet aggregation, suggesting potential as an antiplatelet agent. It exhibits effective antithrombotic activity in the Wistar rat arteriovenous cannula model, reducing thrombus weight at a dose of 5 umol/kg, iv.
Beyond its antiplatelet properties, TNCA also shows anti-inflammatory potential by inhibiting iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells and TNF-alpha-induced NFkappaB activation in human HEK293 cells. It enhances quinone reductase 1 activity in mouse Hepa-1c1c7 cells and inhibits aromatase activity, reflecting potential cytoprotective and enzyme inhibitory functions. Additionally, its antioxidant capability is indicated by a trolox equivalents ratio of 1.68 in the ABTS radical scavenging assay.
Overall, the multifaceted bioactivity profile of TNCA suggests significant therapeutic potential across antiplatelet, antithrombotic, anti-inflammatory, cytoprotective, and antioxidant domains..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | TNCA (Lycoperodine-1) is a high-affinity CaSR ligand (CaSRL) with co-agonist activity. |
| Synonyms | Lycoperodine-1 |
| Molecular Weight | 216.24 |
| Formula | C12H12N2O2 |
| Cas No. | 42438-90-4 |
| Smiles | OC(=O)[C@@H]1Cc2c(CN1)[nH]c1ccccc21 |
| Relative Density. | 1.377g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: < 2.16 mg/mL (10 mM, insoluble or slightly soluble)  | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy TNCA | purchase TNCA | TNCA cost | order TNCA | TNCA chemical structure | TNCA formula | TNCA molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.